Dr Thomas Keating | Director of Biochemistry
Immunogen, Inc.

Dr Thomas Keating, Director of Biochemistry, Immunogen, Inc.

Thomas Keating is Senior Director of Biochemistry at ImmunoGen, leading the research conjugation and characterization group since 2014.  He has also worked previously in anti-infective research and development at AstraZeneca.  He received an A.B. in chemistry from Harvard College, a Ph.D. in synthetic organic chemistry from UCLA, and was a Damon Runyon-Walter Winchell Postdoctoral Fellow with Christopher Walsh at Harvard Medical School.  He has published over 30 peer-reviewed articles

Appearances:



EAC 2017 Day 2, Wednesday 1st November 2017 @ 15:35

Payload considerations for IMGN632, a CD123-targeting ADC for acute myeloid leukemia

  • IMGN632 is a novel ADC linking an anti-CD123 antibody with ImmunoGen’s DGN549 payload via site-specific Cysmab technology
  • DGN549 is a DNA alkylator, as opposed to a DNA cross-linker
  • IMGN632 selectively kills AML cells over normal myeloid progenitors

back to speakers